Defended Amneal in Hatch-Waxman Litigation Involving Generic Pulmonary Fibrosis Drug

June 2021

Genentech, Inc. et al v. Amneal Pharmaceuticals LLC, 1:19-cv-00190-RGA and 1:19-cv-00195-RGA (D. Del.)

Robins Kaplan served as lead counsel to Amneal in Hatch-Waxman patent litigation in the U.S. District Court for the District of Delaware brought by Genentech and Intermune asserting infringement of 15 patents covering Esbriet® (pirfenidone) tablets and 19 patents covering Esbriet® (pirfenidone) capsules.

The case began with more than 16 defendant groups and narrowed down to six at the start of expert discovery. Robins Kaplan was among the leaders of the defense group up until the case resolved after a successful mediation that took place in June 2021.

Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.

Jake M. Holdreith


Managing Partner, Minneapolis Office
Member of Executive Board

Oren D. Langer


Managing Partner, New York Office

Similar Results

Back to Top